Franz Worek

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8871385/publications.pdf

Version: 2024-02-01

250 papers	9,592 citations	47006 47 h-index	53230 85 g-index
253 all docs	253 docs citations	253 times ranked	5225 citing authors

#	Article	IF	Citations
1	Improved determination of acetylcholinesterase activity in human whole blood. Clinica Chimica Acta, 1999, 288, 73-90.	1.1	465
2	Molar absorption coefficients for the reduced Ellman reagent: reassessment. Analytical Biochemistry, 2003, 312, 224-227.	2.4	435
3	Kinetic analysis of interactions between human acetylcholinesterase, structurally different organophosphorus compounds and oximes. Biochemical Pharmacology, 2004, 68, 2237-2248.	4.4	434
4	Differences between organophosphorus insecticides in human self-poisoning: a prospective cohort study. Lancet, The, 2005, 366, 1452-1459.	13.7	327
5	Reactivation kinetics of acetylcholinesterase from different species inhibited by highly toxic organophosphates. Archives of Toxicology, 2002, 76, 523-529.	4.2	241
6	Uptake Mechanism of ApoE-Modified Nanoparticles on Brain Capillary Endothelial Cells as a Blood-Brain Barrier Model. PLoS ONE, 2012, 7, e32568.	2.5	197
7	Respiratory failure in acute organophosphorus pesticide self-poisoning. QJM - Monthly Journal of the Association of Physicians, 2006, 99, 513-522.	0.5	193
8	Fatal sarin poisoning in Syria 2013: forensic verification within an international laboratory network. Forensic Toxicology, 2018, 36, 61-71.	2.4	169
9	Dimethylphosphoryl-inhibited human cholinesterases: inhibition, reactivation, and aging kinetics. Archives of Toxicology, 1999, 73, 7-14.	4.2	158
10	Reappraisal of indications and limitations of oxime therapy in organophosphate poisoning. Human and Experimental Toxicology, 1997, 16, 466-472.	2.2	151
11	Pralidoxime in Acute Organophosphorus Insecticide Poisoningâ€"A Randomised Controlled Trial. PLoS Medicine, 2009, 6, e1000104.	8.4	141
12	Reactivating potency of obidoxime, pralidoxime, HI 6 and HLÃ¶ 7 in human erythrocyte acetylcholinesterase inhibited by highly toxic organophosphorus compounds. Archives of Toxicology, 1998, 72, 237-243.	4.2	137
13	Modern strategies in therapy of organophosphate poisoning. Toxicology Letters, 1999, 107, 233-239.	0.8	137
14	Diagnostic aspects of organophosphate poisoning. Toxicology, 2005, 214, 182-189.	4.2	136
15	The value of novel oximes for treatment of poisoning by organophosphorus compounds. , 2013, 139, 249-259.		131
16	Limitations and challenges in treatment of acute chemical warfare agent poisoning. Chemico-Biological Interactions, 2013, 206, 435-443.	4.0	128
17	Oximes in organophosphate poisoning: 60 years of hope and despair. Chemico-Biological Interactions, 2016, 259, 93-98.	4.0	123
18	Analysis of inhibition, reactivation and aging kinetics of highly toxic organophosphorus compounds with human and pig acetylcholinesterase. Toxicology, 2006, 224, 91-99.	4.2	112

#	Article	IF	Citations
19	Recent advances in evaluation of oxime efficacy in nerve agent poisoning by in vitro analysis. Toxicology and Applied Pharmacology, 2007, 219, 226-234.	2.8	112
20	LC-MS-based procedures for monitoring of toxic organophosphorus compounds and verification of pesticide and nerve agent poisoning. Analytical and Bioanalytical Chemistry, 2008, 391, 97-116.	3.7	109
21	A role for solvents in the toxicity of agricultural organophosphorus pesticides. Toxicology, 2012, 294, 94-103.	4.2	101
22	Human Parathion Poisoning. Toxicological Reviews, 2003, 22, 143-163.	2.5	97
23	Reactivation by various oximes of human erythrocyte acetylcholinesterase inhibited by different organophosphorus compounds. Archives of Toxicology, 1996, 70, 497-503.	4.2	96
24	Organophosphorus compounds and oximes: a critical review. Archives of Toxicology, 2020, 94, 2275-2292.	4.2	95
25	Toxicology of organophosphorus compounds in view of an increasing terrorist threat. Archives of Toxicology, 2016, 90, 2131-2145.	4.2	93
26	Determination of acetylcholinesterase activity by the Ellman assay: A versatile tool for in vitro research on medical countermeasures against organophosphate poisoning. Drug Testing and Analysis, 2012, 4, 282-291.	2.6	92
27	Correlation between red blood cell acetylcholinesterase activity and neuromuscular transmission in organophosphate poisoning. Chemico-Biological Interactions, 2005, 157-158, 345-347.	4.0	90
28	HLÃ¶ 7 dimethanesulfonate, a potent bispyridinium-dioxime against anticholinesterases. Archives of Toxicology, 1992, 66, 603-621.	4.2	88
29	Inhibition, reactivation and aging kinetics of cyclohexylmethylphosphonofluoridate-inhibited human cholinesterases. Archives of Toxicology, 1998, 72, 580-587.	4.2	74
30	Kinetic analysis of reactivation and aging of human acetylcholinesterase inhibited by different phosphoramidates. Biochemical Pharmacology, 2007, 73, 1807-1817.	4.4	74
31	Evaluation of oxime efficacy in nerve agent poisoning: Development of a kinetic-based dynamic model. Toxicology and Applied Pharmacology, 2005, 209, 193-202.	2.8	64
32	Nanoparticulate Transport of Oximes over an In Vitro Blood-Brain Barrier Model. PLoS ONE, 2010, 5, e14213.	2.5	64
33	Structureâ€“activity analysis of aging and reactivation of human butyrylcholinesterase inhibited by analogues of tabun. Biochemical Journal, 2009, 421, 97-106.	3.7	62
34	Suitability of human butyrylcholinesterase as therapeutic marker and pseudo catalytic scavenger in organophosphate poisoning: A kinetic analysis. Toxicology, 2009, 259, 133-139.	4.2	62
35	A structureâ€“activity analysis of the variation in oxime efficacy against nerve agentsâ˜†. Toxicology and Applied Pharmacology, 2008, 231, 157-164.	2.8	61
36	Predicting outcome using butyrylcholinesterase activity in organophosphorus pesticide self-poisoning. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 467-474.	0.5	61

#	Article	IF	Citations
37	HI 6 human serum albumin nanoparticlesâ€"Development and transport over an in vitro bloodâ€"brain barrier model. Toxicology Letters, 2011, 206, 60-66.	0.8	61
38	Lessons to be learnt from organophosphorus pesticide poisoning for the treatment of nerve agent poisoning. Toxicology, 2007, 233, 145-154.	4.2	54
39	Poisoning with the S-Alkyl organophosphorus insecticides profenofos and prothiofos. QJM - Monthly Journal of the Association of Physicians, 2009, 102, 785-792.	0.5	54
40	Obidoxime in acute organophosphate poisoning: 1 â€" clinical effectiveness. Clinical Toxicology, 2009, 47, 798-806.	1.9	52
41	Enzyme-kinetic investigation of different sarin analogues reacting with human acetylcholinesterase and butyrylcholinesterase. Toxicology, 2007, 233, 166-172.	4.2	51
42	Inhibition, reactivation and aging kinetics of highly toxic organophosphorus compounds: Pig versus minipig acetylcholinesterase. Toxicology, 2008, 244, 35-41.	4.2	51
43	Inhibitory Potency against Human Acetylcholinesterase and Enzymatic Hydrolysis of Fluorogenic Nerve Agent Mimics by Human Paraoxonase 1 and Squid Diisopropyl Fluorophosphatase. Biochemistry, 2008, 47, 5216-5224.	2.5	51
44	Reactivation kinetics of a series of related bispyridinium oximes with organophosphate-inhibited human acetylcholinesteraseâ€"Structureâ€"activity relationships. Biochemical Pharmacology, 2012, 83, 1700-1706.	4.4	51
45	Efficacy of the rePON1 mutant IIG1 to prevent cyclosarin toxicity in vivo and to detoxify structurally different nerve agents in vitro. Archives of Toxicology, 2014, 88, 1257-1266.	4.2	51
46	Testing of antidotes for organophosphorus compounds: Experimental procedures and clinical reality. Toxicology, 2007, 233, 108-119.	4.2	49
47	Chromatographic resolution, characterisation and quantification of VX enantiomers in hemolysed swine blood samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 873, 86-94.	2.3	49
48	Extreme variability in the formation of chlorpyrifos oxon (CPO) in patients poisoned by chlorpyrifos (CPF). Biochemical Pharmacology, 2009, 78, 531-537.	4.4	49
49	Restoration of soman-blocked neuromuscular transmission in human and rat muscle by the bispyridinium non-oxime MB327 in vitro. Toxicology, 2012, 294, 80-84.	4.2	49
50	Effect of human plasma on the reactivation of sarin-inhibited human erythrocyte acetylcholinesterase. Archives of Toxicology, 2000, 74, 21-26.	4.2	48
51	Kinetic analysis of the protection afforded by reversible inhibitors against irreversible inhibition of acetylcholinesterase by highly toxic organophosphorus compounds. Biochemical Pharmacology, 2006, 72, 344-357.	4.4	47
52	Swine models in the design of more effective medical countermeasures against organophosphorus poisoning. Toxicology, 2007, 233, 128-144.	4.2	47
53	Structure of a prereaction complex between the nerve agent sarin, its biological target acetylcholinesterase, and the antidote HI-6. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5514-5519.	7.1	46
54	Formation and disposition of diethylphosphoryl-obidoxime, a potent anticholinesterase that is hydrolyzed by human paraoxonase (PON1). Biochemical Pharmacology, 2005, 69, 1853-1867.	4.4	45

#	Article	IF	Citations
55	Reactivation of organophosphate-inhibited human AChE by combinations of obidoxime and HI 6in vitro. Journal of Applied Toxicology, 2007, 27, 582-588.	2.8	45
56	Simultaneous quantification of the organophosphorus pesticides dimethoate and omethoate in porcine plasma and urine by LCâ€“ESI-MS/MS and flow-injection-ESI-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 1234-1245.	2.3	45
57	Catalytic bioscavengers in nerve agent poisoning: A promising approach?. Toxicology Letters, 2016, 244, 143-148.	0.8	43
58	Improving the promiscuous nerve agent hydrolase activity of a thermostable archaeal lactonase. Bioresource Technology, 2010, 101, 9204-9212.	9.6	42
59	Adsorption of obidoxime onto human serum albumin nanoparticles: Drug loading, particle size and drug release. Journal of Microencapsulation, 2010, 27, 506-513.	2.8	42
60	Catalytic efficiencies of directly evolved phosphotriesterase variants with structurally different organophosphorus compounds in vitro. Archives of Toxicology, 2016, 90, 2711-2724.	4.2	42
61	Kinetic analysis of interactions of paraoxon and oximes with human, Rhesus monkey, swine, rabbit, rat and guinea pig acetylcholinesterase. Toxicology Letters, 2011, 200, 19-23.	0.8	41
62	Investigation of the reactivation kinetics of a large series of bispyridinium oximes with organophosphate-inhibited human acetylcholinesterase. Toxicology Letters, 2016, 244, 136-142.	0.8	41
63	The phosphoryl oxime-destroying activity of human plasma. Archives of Toxicology, 2000, 74, 27-32.	4.2	40
64	Detoxification of nerve agents by a substituted Î²-cyclodextrin: Application of a modified biological assay. Toxicology, 2009, 265, 96-100.	4.2	40
65	Post-exposure treatment of VX poisoned guinea pigs with the engineered phosphotriesterase mutant C23: A proof-of-concept study. Toxicology Letters, 2014, 231, 45-54.	0.8	40
66	Detoxification of VX and Other Vâ€Type Nerve Agents in Water at 37â€‰Â°C and pHâ€…7.4 by Substituted Sulfonatocalix[4]arenes. Angewandte Chemie - International Edition, 2016, 55, 12668-12672.	13.8	40
67	An efficient thermostable organophosphate hydrolase and its application in pesticide decontamination. Biotechnology and Bioengineering, 2016, 113, 724-734.	3.3	39
68	Development of antidotes: Problems and strategies. Toxicology, 2007, 233, 23-30.	4.2	38
69	The NADPH oxidase inhibitor diphenyleneiodonium is also a potent inhibitor of cholinesterases and the internal Ca²⁺ pump. British Journal of Pharmacology, 2009, 158, 790-796.	5.4	38
70	Obidoxime in acute organophosphate poisoning: 2 â€“ PK/PD relationships. Clinical Toxicology, 2009, 47, 807-813.	1.9	37
71	Simultaneous quantification of VX and its toxic metabolite in blood and plasma samples and its application for in vivo and in vitro toxicological studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2704-2713.	2.3	37
72	Highly efficient cyclosarin degradation mediated by a Î²-cyclodextrin derivative containing an oxime-derived substituent. Beilstein Journal of Organic Chemistry, 2011, 7, 1543-1554.	2.2	36

#	Article	IF	Citations
73	Forensic evidence of sulfur mustard exposure in real cases of human poisoning by detection of diverse albumin-derived protein adducts. Archives of Toxicology, 2019, 93, 1881-1891.	4.2	36
74	Tabun scavengers based on hydroxamic acid containing cyclodextrins. Chemical Communications, 2013, 49, 3425.	4.1	35
75	Reactivation of organophosphate-inhibited human, Cynomolgus monkey, swine and guinea pig acetylcholinesterase by MMB-4: A modified kinetic approach. Toxicology and Applied Pharmacology, 2010, 249, 231-237.	2.8	34
76	Discovery of a potent non-oxime reactivator of nerve agent inhibited human acetylcholinesterase. European Journal of Medicinal Chemistry, 2018, 157, 151-160.	5.5	34
77	Reversible inhibition of acetylcholinesterase by carbamates or huperzine A increases residual activity of the enzyme upon soman challenge. Toxicology, 2007, 233, 180-186.	4.2	33
78	GCâ€“MS and LCâ€“MS analysis of nerve agents in body fluids: Intra-laboratory verification test using spiked plasma and urine samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 1226-1233.	2.3	33
79	Interaction of bispyridinium compounds with the orthosteric binding site of human Î±7 and Torpedo californica nicotinic acetylcholine receptors (nAChRs). Toxicology Letters, 2011, 206, 100-104.	0.8	33
80	Drug development for the management of organophosphorus poisoning. Expert Opinion on Drug Discovery, 2013, 8, 1467-1477.	5.0	33
81	Bispyridinium Compounds Inhibit Both Muscle and Neuronal Nicotinic Acetylcholine Receptors in Human Cell Lines. PLoS ONE, 2015, 10, e0135811.	2.5	33
82	Red Blood Cell Acetylcholinesterase and Plasma Butyrylcholinesterase Status: Important Indicators for the Treatment of Patients Poisoned by Organophosphorus Compounds. Arhiv Za Higijenu Rada I Toksikologiju, 2007, 58, 359-366.	0.7	32
83	Reactivation of tabun-hAChE investigated by structurally analogous oximes and mutagenesis. Toxicology, 2009, 265, 108-114.	4.2	32
84	New modified Î²-cyclodextrin derivatives as detoxifying agents of chemical warfare agents (I). Synthesis and preliminary screening: Evaluation of the detoxification using a half-quantitative enzymatic assay. Toxicology Letters, 2013, 216, 200-205.	0.8	32
85	Freeze-drying of HI-6-loaded recombinant human serum albumin nanoparticles for improved storage stability. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 510-517.	4.3	32
86	Effects of oximes on muscle force and acetylcholinesterase activity in isolated mouse hemidiaphragms exposed to paraoxon. Toxicology, 2005, 214, 190-197.	4.2	31
87	Development and application of procedures for the highly sensitive quantification of cyclosarin enantiomers in hemolysed swine blood samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 859, 9-15.	2.3	31
88	Atropine maintenance dosage in patients with severe organophosphate pesticide poisoning. Toxicology Letters, 2011, 206, 77-83.	0.8	31
89	Evaluation of the Test-mate ChE (Cholinesterase) Field Kit in Acute Organophosphorus Poisoning. Annals of Emergency Medicine, 2011, 58, 559-564.e6.	0.6	31
90	Preparation and characterization of dialkylphosphoryl-obidoxime conjugates, potent anticholinesterase derivatives that are quickly hydrolyzed by human paraoxonase (PON1192Q). Biochemical Pharmacology, 2007, 74, 1390-1400.	4.4	30

#	Article	IF	Citations
91	Monitoring of neuromuscular transmission in organophosphate pesticide-poisoned patients. Toxicology Letters, 2009, 191, 297-304.	0.8	30
92	Diagnostics and treatment of nerve agent poisoningâ€"current status and future developments. Annals of the New York Academy of Sciences, 2020, 1479, 13-28.	3.8	30
93	Reactivation and aging kinetics of human acetylcholinesterase inhibited by organophosphonylcholines. Archives of Toxicology, 2004, 78, 212-217.	4.2	29
94	Comparison of the oxime-induced reactivation of erythrocyte and muscle acetylcholinesterase following inhibition by sarin or paraoxon, using a perfusion model for the real-time determination of membrane-bound acetylcholinesterase activity. Biochemical Pharmacology, 2008, 75, 698-703.	4.4	29
95	Reactivation kinetics of a homologous series of bispyridinium bis-oximes with nerve agent-inhibited human acetylcholinesterase. Archives of Toxicology, 2012, 86, 1379-1386.	4.2	29
96	Detoxification of organophosphorus pesticides and nerve agents through RSDL: Efficacy evaluation by 31P NMR spectroscopy. Toxicology Letters, 2015, 233, 207-213.	0.8	29
97	In vitro detoxification of cyclosarin (GF) by modified cyclodextrins. Toxicology Letters, 2011, 200, 53-58.	0.8	28
98	In vitro kinetic interactions of pyridostigmine, physostigmine and soman with erythrocyte and muscle acetylcholinesterase from different species. Toxicology Letters, 2011, 206, 41-46.	0.8	28
99	Optimized strategies to synthesize Î²-cyclodextrin-oxime conjugates as a new generation of organophosphate scavengers. Organic and Biomolecular Chemistry, 2011, 9, 3026.	2.8	28
100	Smallâ€scale purification of butyrylcholinesterase from human plasma and implementation of a Î¼LCâ€UV/ESI MS/MS method to detect its organophosphorus adducts. Drug Testing and Analysis, 2015, 7, 947-956.	2.6	27
101	In vitro and in vivo toxicological studies of V nerve agents: Molecular and stereoselective aspects. Toxicology Letters, 2015, 232, 438-448.	0.8	27
102	On-site analysis of acetylcholinesterase and butyrylcholinesterase activity with the ChE check mobile test kitâ€"Determination of reference values and their relevance for diagnosis of exposure to organophosphorus compounds. Toxicology Letters, 2016, 249, 22-28.	0.8	27
103	Effect of atropine and bispyridinium oximes on respiratory and circulatory function in guinea-pigs poisoned by sarin. Toxicology, 1995, 95, 123-133.	4.2	25
104	Detoxification of alkyl methylphosphonofluoridates by an oxime-substituted Î²-cyclodextrin â€" An in vitro structureâ€"activity study. Toxicology Letters, 2014, 224, 209-214.	0.8	25
105	Modification of human serum albumin by the nerve agent VX: microbore liquid chromatography/electrospray ionization highâ€resolution timeâ€ofâ€flight tandem mass spectrometry method for detection of phosphonylated tyrosine and novel cysteine containing disulfide adducts. Rapid Communications in Mass Spectrometry, 2016, 30, 2191-2200.	1.5	25
106	Bioanalytical verification of V-type nerve agent exposure: simultaneous detection of phosphonylated tyrosines and cysteine-containing disulfide-adducts derived from human albumin. Analytical and Bioanalytical Chemistry, 2018, 410, 1463-1474.	3.7	25
107	Pharmacokinetics of obidoxime in patients poisoned with organophosphorus compounds. Toxicology Letters, 2010, 197, 236-242.	0.8	24
108	Functionalized cyclodextrins bearing an alpha nucleophile â€" A promising way to degrade nerve agents. Chemico-Biological Interactions, 2013, 203, 202-207.	4.0	24

#	Article	IF	Citations
109	Toxicokinetic Aspects of Nerve Agents and Vesicants. , 2015, , 817-856.		24
110	Reactivation kinetics of 31 structurally different bispyridinium oximes with organophosphate-inhibited human butyrylcholinesterase. Archives of Toxicology, 2015, 89, 405-414.	4.2	24
111	Single treatment of VX poisoned guinea pigs with the phosphotriesterase mutant C23AL: Intraosseous versus intravenous injection. Toxicology Letters, 2016, 258, 198-206.	0.8	24
112	Development of a dynamic model for real-time determination of membrane-bound acetylcholinesterase activity upon perfusion with inhibitors and reactivators. Biochemical Pharmacology, 2006, 72, 358-365.	4.4	23
113	Identical kinetics of human erythrocyte and muscle acetylcholinesterase with respect to carbamate pre-treatment, residual activity upon soman challenge and spontaneous reactivation after withdrawal of the inhibitors. Toxicology, 2008, 246, 188-192.	4.2	23
114	Effectiveness of a substituted Î²-cyclodextrin to prevent cyclosarin toxicity in vivo. Toxicology Letters, 2014, 226, 222-227.	0.8	23
115	Kinetic analysis of interactions between alkylene-linked bis-pyridiniumaldoximes and human acetylcholinesterases inhibited by various organophosphorus compounds. Biochemical Pharmacology, 2010, 80, 941-946.	4.4	22
116	Affinities of bispyridinium non-oxime compounds to [3H]epibatidine binding sites of Torpedo californica nicotinic acetylcholine receptors depend on linker length. Chemico-Biological Interactions, 2013, 206, 545-554.	4.0	22
117	Oximes. , 0, , 305-329.		22
118	Equipotent cholinesterase reactivation in vitro by the nerve agent antidotes HI 6 dichloride and HI 6 dimethanesulfonate. Archives of Toxicology, 2002, 76, 589-595.	4.2	21
119	Assessment of neuromuscular dysfunction during poisoning by organophosphorus compounds. Chemico-Biological Interactions, 2010, 187, 265-269.	4.0	21
120	Detoxification of tabun at physiological pH mediated by substituted Î²-cyclodextrin and glucose derivatives containing oxime groups. Toxicology, 2012, 302, 163-171.	4.2	21
121	Development of MS Binding Assays targeting the binding site of MB327 at the nicotinic acetylcholine receptor. Toxicology Letters, 2018, 293, 172-183.	0.8	21
122	Comparison of the oxime-induced reactivation of rhesus monkey, swine and guinea pig erythrocyte acetylcholinesterase following inhibition by sarin or paraoxon, using a perfusion model for the real-time determination of membrane-bound acetylcholinesterase activity. Toxicology, 2009, 258, 79-83.	4.2	20
123	Development and validation of a sensitive gas chromatographyâ€“ammonia chemical ionization mass spectrometry method for the determination of tabun enantiomers in hemolysed blood and plasma of different species. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 1290-1296.	2.3	20
124	Aging mechanism of butyrylcholinesterase inhibited by an N-methyl analogue of tabun: Implications of the trigonalâ€“bipyramidal transition state rearrangement for the phosphylation or reactivation of cholinesterases. Chemico-Biological Interactions, 2010, 187, 44-48.	4.0	20
125	Immobilization of Russian VX skin depots by localized cooling: Implications for decontamination and medical countermeasures. Toxicology Letters, 2011, 206, 47-53.	0.8	20
126	Paradox findings may challenge orthodox reasoning in acute organophosphate poisoning. Chemico-Biological Interactions, 2010, 187, 270-278.	4.0	19

#	Article	IF	Citations
127	Toxicokinetics of tabun enantiomers in anaesthetized swine after intravenous tabun administration. Toxicology Letters, 2010, 198, 177-181.	0.8	19
128	In vitro kinetic interactions of DEET, pyridostigmine and organophosphorus pesticides with human cholinesterases. Chemico-Biological Interactions, 2011, 190, 79-83.	4.0	19
129	Comparative kinetics of organophosphates and oximes with erythrocyte, muscle and brain acetylcholinesterase. Toxicology Letters, 2012, 209, 173-178.	0.8	19
130	Investigation of kinetic interactions between approved oximes and human acetylcholinesterase inhibited by pesticide carbamates. Chemico-Biological Interactions, 2013, 206, 569-572.	4.0	19
131	New modified Î²-cyclodextrin derivatives as detoxifying agents of chemical warfare agents (II). In vitro detoxification of cyclosarin (GF): General screening and toxicokinetic aspects of OP scavengers. Toxicology Letters, 2013, 216, 206-212.	0.8	19
132	Functional analysis of Torpedo californica nicotinic acetylcholine receptors in multiple activation states by SSM-based electrophysiology. Toxicology Letters, 2016, 247, 1-10.	0.8	19
133	Identification of novel disulfide adducts between the thiol containing leaving group of the nerve agent VX and cysteine containing tripeptides derived from human serum albumin. Drug Testing and Analysis, 2017, 9, 1192-1203.	2.6	19
134	Precision cut lung slices as test system for candidate therapeutics in organophosphate poisoning. Toxicology, 2017, 389, 94-100.	4.2	19
135	Reevaluation of indirect field stimulation technique to demonstrate oxime effectiveness in OP-poisoning in muscles in vitro. Toxicology, 2007, 233, 209-213.	4.2	18
136	Muscle force and acetylcholinesterase activity in mouse hemidiaphragms exposed to paraoxon and treated by oximes in vitro. Toxicology, 2010, 272, 46-51.	4.2	18
137	Comparative study of oxime-induced reactivation of erythrocyte and muscle AChE from different animal species following inhibition by sarin or paraoxon. Toxicology Letters, 2010, 194, 94-101.	0.8	18
138	Chromatographic preparation and kinetic analysis of interactions between tabun enantiomers and acetylcholinesterase. Toxicology Letters, 2010, 195, 142-146.	0.8	18
139	The therapeutic use of localized cooling in the treatment of VX poisoning. Toxicology Letters, 2011, 204, 52-56.	0.8	18
140	Structural requirements for effective oximes â€“ Evaluation of kinetic in vitro data with phosphylated human AChE and structurally different oximes. Chemico-Biological Interactions, 2013, 203, 125-128.	4.0	18
141	Reactivation of Plasma Butyrylcholinesterase by Pralidoxime Chloride in Patients Poisoned by WHO Class II Toxicity Organophosphorus Insecticides. Toxicological Sciences, 2013, 136, 274-283.	3.1	18
142	Novel cysteine- and albumin-adduct biomarkers to prove human poisoning with the pesticide oxydemeton-S-methyl. Toxicology Letters, 2018, 294, 122-134.	0.8	18
143	Chromatographic analysis of toxic phosphylated oximes (POX): a brief overview. Drug Testing and Analysis, 2010, 2, 460-468.	2.6	17
144	Reactivation of organophosphate-inhibited human acetylcholinesterase by isonitrosoacetone (MINA): A kinetic analysis. Chemico-Biological Interactions, 2011, 194, 91-96.	4.0	17

#	Article	IF	Citations
145	Competition radioligand binding assays for the investigation of bispyridinium compound affinities to the human muscarinic acetylcholine receptor subtype 5 (hM₅). Drug Testing and Analysis, 2012, 4, 292-297.	2.6	17
146	InÂvitro evaluation of the catalytic activity of paraoxonases and phosphotriesterases predicts the enzyme circulatory levels required for inÂvivo protection against organophosphate intoxications. Chemico-Biological Interactions, 2016, 259, 252-256.	4.0	17
147	Application of the Ugi Multicomponent Reaction in the Synthesis of Reactivators of Nerve Agent Inhibited Acetylcholinesterase. Journal of Medicinal Chemistry, 2017, 60, 9376-9392.	6.4	17
148	In vitro pharmacological characterization of the bispyridinium non-oxime compound MB327 and its 2- and 3-regioisomers. Toxicology Letters, 2018, 293, 190-197.	0.8	17
149	Effect of organophosphorus hydrolysing enzymes on obidoxime-induced reactivation of organophosphate-inhibited human acetylcholinesterase. Archives of Toxicology, 2004, 78, 338-343.	4.2	16
150	Development of a high-throughput screening for nerve agent detoxifying materials using a fully-automated robot-assisted biological assay. Toxicology in Vitro, 2010, 24, 1026-1031.	2.4	16
151	In vitro kinetics of nerve agent degradation by fresh frozen plasma (FFP). Archives of Toxicology, 2014, 88, 301-307.	4.2	16
152	Kinetic analysis of interactions of amodiaquine with human cholinesterases and organophosphorus compounds. Toxicology Letters, 2016, 246, 49-56.	0.8	16
153	Evaluation of medical countermeasures against organophosphorus compounds: The value of experimental data and computer simulations. Chemico-Biological Interactions, 2010, 187, 259-264.	4.0	15
154	Incorporation of obidoxime into human serum albumin nanoparticles: optimisation of preparation parameters for the development of a stable formulation. Journal of Microencapsulation, 2010, 27, 594-601.	2.8	15
155	Effect of MB327 and oximes on rat intestinal smooth muscle function. Chemico-Biological Interactions, 2013, 204, 1-5.	4.0	15
156	Counteracting desensitization of human Î±7-nicotinic acetylcholine receptors with bispyridinium compounds as an approach against organophosphorus poisoning. Toxicology Letters, 2018, 293, 149-156.	0.8	15
157	Estimation of oxime efficacy in nerve agent poisoning: A kinetic approach. Chemico-Biological Interactions, 2005, 157-158, 349-352.	4.0	14
158	Application of kinetic-based computer modelling to evaluate the efficacy of HI 6 in percutaneous VX poisoning. Toxicology, 2006, 224, 74-80.	4.2	14
159	Interactions between acetylcholinesterase, toxic organophosphorus compounds and a short series of structurally related non-oxime reactivators: Analysis of reactivation and inhibition kinetics in vitro. Toxicology Letters, 2018, 299, 218-225.	0.8	14
160	A case report of cholinesterase inhibitor poisoning: cholinesterase activities and analytical methods for diagnosis and clinical decision making. Archives of Toxicology, 2020, 94, 2239-2247.	4.2	14
161	Direct reaction of oximes with crotylsarin, cyclosarin, or VX in vitro. Archives of Toxicology, 2007, 81, 415-420.	4.2	13
162	Toxicokinetics of Chemical Warfare Agents. , 2009, , 755-790.		13

#	Article	IF	Citations
163	Kinetic analysis of interactions of different sarin and tabun analogues with human acetylcholinesterase and oximes: Is there a structureâ€“activity relationship?. Chemico-Biological Interactions, 2010, 187, 215-219.	4.0	13
164	Detoxification of G- and V-series nerve agents by the phosphotriesterase OpdA. Biocatalysis and Biotransformation, 2012, 30, 203-208.	2.0	13
165	Reactivation of nerve agent-inhibited human acetylcholinesterase by obidoxime, HI-6 and obidoxime+HI-6: Kinetic in vitro study with simulated nerve agent toxicokinetics and oxime pharmacokinetics. Toxicology, 2016, 350-352, 25-30.	4.2	13
166	Innovative Biocatalysts as Tools to Detect and Inactivate Nerve Agents. Scientific Reports, 2018, 8, 13773.	3.3	13
167	Toxicokinetic aspects of nerve agents and vesicants. , 2020, , 875-919.		13
168	Elimination kinetics and molecular reaction mechanisms of cyclosarin (GF) by an oxime substituted Î²-cyclodextrin derivative in vitro. Toxicology Letters, 2015, 239, 41-52.	0.8	12
169	Efficacy of an organophosphorus hydrolase enzyme (OpdA) in human serum and minipig models of organophosphorus insecticide poisoning. Clinical Toxicology, 2020, 58, 397-405.	1.9	12
170	A catalytic bioscavenger with improved stability and reduced susceptibility to oxidation for treatment of acute poisoning with neurotoxic organophosphorus compounds. Toxicology Letters, 2020, 321, 138-145.	0.8	12
171	Structural and Functional Characterization of New SsoPox Variant Points to the Dimer Interface as a Driver for the Increase in Promiscuous Paraoxonase Activity. International Journal of Molecular Sciences, 2020, 21, 1683.	4.1	12
172	Intoxication with Huperzine A, a Potent Anticholinesterase Found in the Fir Club Moss. Journal of Toxicology: Clinical Toxicology, 2000, 38, 803-808.	1.5	11
173	In vitro toxicokinetic studies of cyclosarin: Molecular mechanisms of elimination. Toxicology Letters, 2014, 227, 1-11.	0.8	11
174	Kinetic interactions of a homologous series of bispyridinium monooximes (HGG oximes) with native and phosphonylated human acetylcholinesterase. Toxicology Letters, 2012, 212, 29-32.	0.8	10
175	Electrophysiological investigation of the effect of structurally different bispyridinium non-oxime compounds on human Î±7-nicotinic acetylcholine receptor activityâ€”An in vitro structure-activity analysis. Toxicology Letters, 2018, 293, 157-166.	0.8	10
176	Synthesis of a Series of Structurally Diverse MB327 Derivatives and Their Affinity Characterization at the Nicotinic Acetylcholine Receptor. ChemMedChem, 2018, 13, 1806-1816.	3.2	10
177	COPD and asthma therapeutics for supportive treatment in organophosphate poisoning. Clinical Toxicology, 2019, 57, 644-651.	1.9	10
178	Simulation of cholinesterase status at different scenarios of nerve agent exposure. Toxicology, 2007, 233, 155-165.	4.2	9
179	Effects of oximes on rate of decarbamylation of human red blood cell AChE measured with two different methods. Biochemical Pharmacology, 2008, 75, 1561-1566.	4.4	9
180	Reactions of isodimethoate with human red cell acetylcholinesterase. Biochemical Pharmacology, 2008, 75, 2045-2053.	4.4	9

#	Article	IF	Citations
181	Restoration of nerve agent inhibited muscle force production in human intercostal muscle strips with HI 6. Toxicology Letters, 2011, 206, 72-76.	0.8	9
182	Pre- and post-treatment effect of physostigmine on soman-inhibited human erythrocyte and muscle acetylcholinesterase in vitro. Toxicology and Applied Pharmacology, 2011, 253, 7-13.	2.8	9
183	Effect of different buffers on kinetic properties of human acetylcholinesterase and the interaction with organophosphates and oximes. Archives of Toxicology, 2011, 85, 193-198.	4.2	9
184	Application of an enantioselective LCâ€ESI MS/MS procedure to determine Râ€•and Sâ€hyoscyamine following intravenous atropine administration in swine. Drug Testing and Analysis, 2012, 4, 194-198.	2.6	9
185	Pseudocatalytic scavenging of the nerve agent VX with human blood components and the oximes obidoxime and HI-6. Archives of Toxicology, 2017, 91, 1309-1318.	4.2	9
186	Alteration of miRNA expression in a sulfur mustard resistant cell line. Toxicology Letters, 2018, 293, 38-44.	0.8	9
187	Searching for putative binding sites of the bispyridinium compound MB327 in the nicotinic acetylcholine receptor. Toxicology Letters, 2018, 293, 184-189.	0.8	9
188	Synthesis of a Series of Nonâ€Symmetric Bispyridinium and Related Compounds and Their Affinity Characterization at the Nicotinic Acetylcholine Receptor. ChemMedChem, 2018, 13, 2653-2663.	3.2	9
189	Are we using the right dose? â€“ A tale of mole and gram. British Journal of Clinical Pharmacology, 2008, 66, 451-452.	2.4	8
190	Interaction of pentylsarin analogues with human acetylcholinesterase: A kinetic study. Toxicology Letters, 2009, 187, 119-123.	0.8	8
191	Kinetic prerequisites of oximes as effective reactivators of organophosphate-inhibited acetylcholinesterase: a theoretical approach. Journal of Enzyme Inhibition and Medicinal Chemistry, 2011, 26, 303-308.	5.2	8
192	Central respiratory effects on motor nerve activities after organophosphate exposure in a working heart brainstem preparation of the rat. Toxicology Letters, 2011, 206, 94-99.	0.8	8
193	Elimination pathways of cyclosarin (GF) mediated by Î²-cyclodextrin in vitro: Pharmacokinetic and toxicokinetic aspects. Toxicology Letters, 2013, 222, 164-170.	0.8	8
194	Pathways for the Reactions Between Neurotoxic Organophosphorus Compounds and Oximes or Hydroxamic Acids. European Journal of Organic Chemistry, 2016, 2016, 5831-5838.	2.4	8
195	Effects of anti-inflammatory compounds on sulfur mustard injured cells: Recommendations and caveats suggested by in vitro cell culture models. Toxicology Letters, 2018, 293, 91-97.	0.8	8
196	Sulfur mustard resistant keratinocytes obtained elevated glutathione levels and other changes in the antioxidative defense mechanism. Toxicology Letters, 2018, 293, 51-61.	0.8	8
197	Translating the Concept of Bispecific Antibodies to Engineering Heterodimeric Phosphotriesterases with Broad Organophosphate Substrate Recognition. Biochemistry, 2020, 59, 4395-4406.	2.5	8
198	Catalytic activity and stereoselectivity of engineered phosphotriesterases towards structurally different nerve agents in vitro. Archives of Toxicology, 2021, 95, 2815-2823.	4.2	8

#	Article	IF	Citations
199	Investigation of cardiac glycosides from oleander in a human induced pluripotent stem cells derived cardiomyocyte model. Toxicology Letters, 2021, 350, 261-266.	0.8	8
200	Organophosphorus pesticides exhibit compound specific effects in rat precision-cut lung slices (PCLS): mechanisms involved in airway response, cytotoxicity, inflammatory activation and antioxidative defense. Archives of Toxicology, 2022, 96, 321-334.	4.2	8
201	Effect of metoclopramide and ranitidine on the inhibition of human AChE by VXin vitro. Journal of Applied Toxicology, 2005, 25, 568-571.	2.8	7
202	Quantification of pralidoxime (2â€PAM) in urine by ion pair chromatographyâ€diode array detection: application to in vivo samples from minipig. Drug Testing and Analysis, 2012, 4, 169-178.	2.6	7
203	Bispyridinium non-oximes: An evaluation of cardiac effects in isolated hearts and smooth muscle relaxing effects in jejunum. Toxicology in Vitro, 2016, 35, 11-16.	2.4	7
204	Kinetics of pesticide degradation by human fresh frozen plasma (FFP) in vitro. Toxicology Letters, 2016, 244, 124-128.	0.8	7
205	The arrhythmogenic potential of nerve agents and a cardiac safety profile of antidotes - A proof-of-concept study using human induced pluripotent stem cells derived cardiomyocytes (hiPSC-CM). Toxicology Letters, 2019, 308, 1-6.	0.8	7
206	Human small bowel as model for poisoning with organophosphorus compounds. Toxicology in Vitro, 2019, 57, 76-80.	2.4	7
207	In Vitro Interaction of Organophosphono- and Organophosphorothioates with Human Acetylcholinesterase. Molecules, 2020, 25, 3029.	3.8	7
208	Development of versatile and potent monoquaternary reactivators of acetylcholinesterase. Archives of Toxicology, 2021, 95, 985-1001.	4.2	7
209	Synthesis and in vitro evaluation of novel non-oximes for the reactivation of nerve agent inhibited human acetylcholinesterase. Chemico-Biological Interactions, 2020, 326, 109139.	4.0	7
210	Optimization of long-term cold storage of rat precision-cut lung slices with a tissue preservation solution. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L1023-L1035.	2.9	7
211	Evaluation of 6,6â€²-dithionicotinic acid as alternative chromogen in a modified Ellman methodâ€”comparison in various species. Toxicology Mechanisms and Methods, 2011, 21, 533-537.	2.7	6
212	Investigations of kinetic interactions between lipid emulsions, hydroxyethyl starch or dextran and organophosphorus compounds. Clinical Toxicology, 2013, 51, 918-922.	1.9	6
213	Repetitive obidoxime treatment induced increase of red blood cell acetylcholinesterase activity even in a late phase of a severe methamidophos poisoning: A case report. Toxicology Letters, 2016, 244, 121-123.	0.8	6
214	The in vitro protective effects of the three novel nanomolar reversible inhibitors of human cholinesterases against irreversible inhibition by organophosphorous chemical warfare agents. Chemico-Biological Interactions, 2019, 309, 108714.	4.0	6
215	Evaluation of the accuracy of â€œChE check mobileâ€•in measurement of acetylcholinesterase in pesticide poisoning. Clinical Toxicology, 2019, 57, 411-414.	1.9	6
216	Post-VX exposure treatment of rats with engineered phosphotriesterases. Archives of Toxicology, 2022, 96, 571-583.	4.2	6

#	Article	IF	Citations
217	The liberation of thiocholine from acetylthiocholine (ASCh) by pralidoxime iodide (2=PAM) and other oximes (obidoxime and diacetylmonoxime). Toxicology Letters, 2006, 167, 256-257.	0.8	5
218	Evaluation of HI 6 treatment after percutaneous VR exposure by use of a kinetic-based dynamic computer model. Toxicology, 2007, 233, 173-179.	4.2	5
219	Kinetic Analysis of Oxime Interactions with Acetylcholinesterase as a Basis for the Evaluation of Oxime Efficacy in Organophosphate Poisoning. Current Bioactive Compounds, 2010, 6, 16-22.	0.5	5
220	Effect of reversible ligands on oxime-induced reactivation of sarin- and cyclosarin-inhibited human acetylcholinesterase. Toxicology Letters, 2015, 232, 557-565.	0.8	5
221	Adaptation of a dynamic in vitro model with real-time determination of butyrylcholinesterase activity in the presence of cyclosarin and an oxime. Toxicology in Vitro, 2015, 29, 162-167.	2.4	5
222	Entgiftung von VX und anderen Vâ€Stoffen in Wasser bei 37â€‰Â°C und pHâ€…7.4 durch substituierte Sulfonatocalix[4]arene. Angewandte Chemie, 2016, 128, 12859-12863.	2.0	5
223	An Unusual Dimeric Inhibitor of Acetylcholinesterase: Cooperative Binding of Crystal Violet. Molecules, 2017, 22, 1433.	3.8	5
224	Influence of cyclic and acyclic cucurbiturils on the degradation pathways of the chemical warfare agent VX. Organic and Biomolecular Chemistry, 2020, 18, 5218-5227.	2.8	5
225	Evaluation of Functional and Structural Alterations in Muscle Tissue after Short-Term Cold Storage in a New Tissue Preservation Solution. Cells Tissues Organs, 2011, 194, 501-509.	2.3	4
226	Blaptica dubia as sentinels for exposure to chemical warfare agents â€“ a pilot study. Toxicology Letters, 2016, 262, 12-16.	0.8	4
227	Self-regeneration of neuromuscular function following soman and VX poisoning in spinal cordâ€”skeletal muscle cocultures. Toxicology Letters, 2016, 244, 149-153.	0.8	4
228	Development of a sensitive, generic and easy to use organophosphate skin disclosure kit. Toxicology Letters, 2017, 280, 190-194.	0.8	4
229	The oximes HI-6 and MMB-4 fail to reactivate soman-inhibited human and guinea pig AChE: A kinetic in vitro study. Toxicology Letters, 2018, 293, 216-221.	0.8	4
230	Early diagnosis of nerve agent exposure with a mobile test kit and implications for medical countermeasures: a trigger to react. BMJ Military Health, 2020, 166, 99-102.	0.9	4
231	Pro: Oximes should be used routinely in organophosphate poisoning. British Journal of Clinical Pharmacology, 2022, 88, 5064-5069.	2.4	4
232	Broadâ€Spectrum Antidote Discovery by Untangling the Reactivation Mechanism of Nerveâ€Agentâ€Inhibited Acetylcholinesterase. Chemistry - A European Journal, 2022, 28, .	3.3	4
233	Comments on â€œEfficacy of two new asymmetric bispyridinium oximes (K-27 and K-48) in rats exposed to diisopropylfluorophosphate: Comparison with pralidoxime, obidoxime, trimedoxime, methoxime, and HI 6â€. Toxicology Mechanisms and Methods, 2009, 19, 334-334.	2.7	3
234	Photostability of antidotal oxime HIâ€6, impact on drug development. Drug Testing and Analysis, 2012, 4, 208-214.	2.6	3

#	Article	IF	Citations
235	Reversedâ€phase ionâ€pair chromatographyâ€diode array detection of the bispyridinium compound MB327: plasma analysis of a potential novel antidote for the treatment of organophosphorus poisoning. Drug Testing and Analysis, 2016, 8, 154-163.	2.6	3
236	Anesthetic actions of thiopental remain largely unaffected during cholinergic overstimulation in cultured cortical networks. Toxicology Letters, 2016, 244, 129-135.	0.8	3
237	New Resensitizers for the Nicotinic Acetylcholine Receptor by Ligand-Based Pharmacophore Modeling. Current Computer-Aided Drug Design, 2018, 15, 104-109.	1.2	3
238	Reactions of methylphosphonic difluoride with human acetylcholinesterase and oximes â€“ Possible therapeutic implications. Toxicology Letters, 2014, 231, 92-98.	0.8	2
239	Application of a dynamic in vitro model with real-time determination of acetylcholinesterase activity for the investigation of tabun analogues and oximes. Toxicology in Vitro, 2015, 30, 514-520.	2.4	2
240	Immediate responses of the cockroach Blaptica dubia after the exposure to sulfur mustard. Archives of Toxicology, 2018, 92, 337-346.	4.2	2
241	Human small bowel as a useful tool to investigate smooth muscle effects of potential therapeutics in organophosphate poisoning. Toxicology Letters, 2018, 293, 235-240.	0.8	2
242	Release of protein-bound nerve agents by excess fluoride from whole blood: GC-MS/MS method development, validation, and application to a real-life denatured blood sample. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1179, 122693.	2.3	2
243	Midazolam is effective to reduce cortical network activity in organotypic cultures during severe cholinergic overstimulation with soman. Toxicology Letters, 2018, 297, 19-23.	0.8	1
244	Effect of cholinergic crisis on the potency of different emergency anaesthesia protocols in soman-poisoned rats. Clinical Toxicology, 2019, 57, 343-349.	1.9	1
245	Screening of chiral shift reagents suitable to generically separate the enantiomers of V-agents by 31P-NMR spectroscopy. Toxicology Letters, 2020, 320, 28-36.	0.8	1
246	Thirteenth International Medical Chemical Defence Conference 2011 â€œNew developments in the treatment of intoxications by chemical warfare agents with focus on neurotoxic agentsâ€. Toxicology Letters, 2011, 206, 3-4.	0.8	0
247	In vitro kinetic interactions of DEET, pyridostigmine and organophosphorus pesticides with human cholinesterases â€“ Response to the letter to the editor. Chemico-Biological Interactions, 2011, 193, 108.	4.0	0
248	Front Cover: Pathways for the Reactions Between Neurotoxic Organophosphorus Compounds and Oximes or Hydroxamic Acids (Eur. J. Org. Chem. 35/2016). European Journal of Organic Chemistry, 2016, 2016, 5777-5777.	2.4	0
249	Impact of soman and acetylcholine on the effects of propofol in cultured cortical networks. Toxicology Letters, 2020, 322, 98-103.	0.8	0
250	Inhibition of an organophosphate-detoxifying bacterial phosphotriesterase by albumin and plasma thiol components. Toxicology Letters, 2021, 350, 194-201.	0.8	0